$CUE DD: Multi-Catalyst Immunology Platform With Multiple Shots on Goal 🧬

Been digging into **Cue Biopharma ($CUE)** and it looks like an interesting small-cap biotech setting up for several potential catalysts over the next 6-12 months.

**What they do:**
Cue is developing precision immunotherapies designed to selectively activate or regulate immune responses across cancer, autoimmune, and allergic diseases. Rather than being a one-asset story, they’re building a broader immunology platform with multiple programs in development.

**Recent developments that caught my attention:**
✅ Potential **$345M partnership** with Boehringer Ingelheim
✅ Received a **$7.5M milestone payment** in April 2026
✅ Lead allergy program advancing through **Phase 2**, with data expected in **2H 2026**
✅ **Q1 revenue increased to $5.7M** vs. $0.4M in the prior-year quarter
✅ **Net loss narrowed significantly** year-over-year
✅ New CEO **Shao Lee Lin** brings substantial biotech leadership experience

**Why it could be worth watching:**
Multiple upcoming catalysts instead of relying on a single binary event
Partnership validation from a major pharma company
Improving financial metrics
Potential value inflection from upcoming clinical data